A lyophilized drinking-water powder represents the primary downstream presentation for live B26-T1200 in broiler-producing flocks where mass application via nipple lines or bell drinkers is the standard route. The API is harvested from submerged culture and mixed with a lyoprotective matrix before freeze-drying. A representative stabilizer composition containing 5% w/v sucrose, 2% w/v gelatin and 1% w/v sodium glutamate is used to raise the collapse temperature of the frozen cake and preserve cold-chain viability. The filled vials are loaded onto stainless-steel lyophilizer shelves and freeze-dried with a primary drying shelf temperature of -30 °C to -20 °C under a chamber pressure of 0.10–0.20 mbar. Secondary drying proceeds at +20 °C to +25 °C until the residual moisture is below 3.0% as determined by USP <921> Method Ic. The finished cake is vacuum-stoppered in 1000-dose Type I borosilicate vials and stored at 2–8 °C. Release viabilities are quantified by plate count on blood agar at 37 °C for 48 h, with strain-specific titers validated during product registration. Drinking-water reconstitution requires water free of chlorine, copper ions and quaternary ammonium disinfectants. Municipal water suspected of residual chlorine is neutralized with sodium thiosulfate at 0.1 g/L before the vaccine is added. Reconstituted vaccine should be consumed within 2 h at 25 °C or 4 h at 10 °C. Published data for B26-T1200 at ambient temperatures above 30 °C are limited. The lyophilized powder must be protected from direct sunlight during mixing because ultraviolet exposure can reduce viability in unprotected vessels. Master seed lot identity, safety and potency for live avian Pasteurella multocida products are assessed under USDA 9 CFR 113.70. The regulation covers identity by agglutination or molecular typing, safety in susceptible birds, and potency by vaccination-challenge efficacy. Cold-chain shipment uses insulated containers with validated phase-change materials capable of maintaining 2–8 °C for 72 h. Temperature excursions above 25 °C for more than 2 h during transport require quarantine and viability retesting before farm delivery.

The drinking-water powder is not suitable for direct injection and must not be reconstituted with saline containing preservatives or bacteriostatic agents. Preservatives such as benzyl alcohol at 0.9% w/v can reduce live cell recovery by more than 2.0 log10 CFU within 30 min in standard live bacterial suspensions. Filling of the lyophilized powder into vials is conducted in an ISO 14644-1:2015 Class 7 cleanroom with continuous viable particle monitoring. The finished product is rejected if visible cake collapse exceeds 10% of the vial bottom area because collapsed regions contain amorphous water pockets that destabilize the live cells. Batch release for export markets requires a certificate of analysis listing residual moisture, vial vacuum, and viable count per dose. Live count at release is generally controlled at 1×10^8 to 1×10^9 CFU per dose; however, the exact strain-specific release range for B26-T1200 is confidential to the marketing authorization holder and is not published in public pharmacopeial monographs.

Does Low Ionic Strength Diluent Depress Live B26-T1200 Culturability Before Wing-Web Administration?

Low ionic strength diluents can impose osmotic shock on live Pasteurella multocida cells immediately after reconstitution. The injectable presentation therefore requires a sterile diluent with an osmolality between 280 mOsm/kg and 320 mOsm/kg. Aqueous phosphate-buffered saline with 0.01 M phosphate and 0.2% w/v gelatin has been used as a stabilizing diluent for live bacterial vaccines. Pre-warming of the diluent to 15–20 °C reduces clumping during reconstitution. The reconstituted suspension is aseptically transferred to fixed-volume poultry vaccinators with 0.5 mL dose capacity. Syringe dead volume must be purged before use. The suspension is held on ice packs at 2–8 °C and used within 2 h. Unused suspension is discarded. Freezing the reconstituted product is contraindicated. Freeze-thaw stress reduces colony-forming units by 1.0–1.5 log10 CFU/mL when measured by plate count after 48 h incubation. Sterility of the injectable blend is verified according to USP <71> and Ph. Eur. 2.6.1. Bacterial endotoxin levels are controlled in the diluent and primary packaging components because live vaccine suspensions may be administered parenterally. The stopper and seal configuration must meet ISO 11040-2 prefillable syringe requirements when prefilled syringes are used. Parenteral administration route is determined by the registered label; wing-web and subcutaneous routes are evaluated in target bird safety studies under USDA 9 CFR 113.70. The injectable product is not a self-adjuvanting formulation. Live B26-T1200 cells must not be mixed with oil-in-water adjuvants in the same syringe unless a compatibility test has established viability retention of at least 70% after 2 h contact time. Published data for this specific construct in adjuvant blends are limited; therefore, segregation of reconstituted live vaccine and inactivated emulsion vaccines into separate vaccination crews is standard practice.

Feed-mill incorporation shifts the stability burden from cold-chain transport to acid-stable granule architecture. Live bacterial vaccines in feed premixes face low pH in the proventriculus and friction during mixing. A wet granulation process using sodium alginate at 1.5% w/v and calcium carbonate at 0.5% w/v creates a pH-responsive matrix that delays cell release until the duodenal lumen. The granule fraction is screened to 250–800 µm. Mixing uniformity in a ribbon blender requires a coefficient of variation below 5% after 10 min of blending at 30 rpm. Pellet conditioning above 70 °C must be avoided; post-pellet liquid application is preferred for thermolabile live particles. Final feed moisture is maintained below 13% to keep water activity below 0.65. Viable count per gram of premix is monitored by plate count on blood agar at 37 °C for 48 h. Recovery is expressed as CFU per gram of finished feed. Strain-specific release titers for B26-T1200 in extruded feed matrices are not published in public pharmacopoeial monographs, so a process-specific validation is required before first commercial use. Feed-grade carriers such as wheat middlings or rice hulls are avoided unless heat-treated and neutral-pH certified. The granule blend is packaged in multi-wall paper bags with a polyethylene inner liner and stored at 2–8 °C for a shelf life determined by real-time stability. In the EU, incorporating a live bacterial vaccine into a feed premix triggers veterinary medicinal product requirements under Regulation (EU) 2019/6, including batch-to-batch consistency testing and residue documentation. Operators handling the premix must use dust-control measures because airborne live particles can colonize unprotected mucous membranes. Feed-mill equipment cleaning after a live vaccine premix campaign requires a validated flush sequence of at least 3 complete batch cycles with non-medicated carrier to prevent cross-contamination.

When Hard Gelatin Capsules Are Selected for Small-Hold Flock Cholera Control

Hard gelatin capsules are considered when individual bird dosing is required and water-system vaccination cannot guarantee uniform intake. The live API is blended with mannitol and trehalose dihydrate at a 1:1 ratio before filling. Each capsule contains 200 mg ±5% of the blend. The capsule shells are enteric-coated with methacrylic acid copolymer dispersion applied at 5 mg/cm² dry coating weight. Disintegration is delayed until the pH exceeds 5.5; this avoids gastric acid inactivation of non-encapsulated live cells. Dissolution testing uses USP Apparatus II at 50 rpm in 0.1 N HCl for 2 h, followed by phosphate buffer pH 6.8. Viable count per capsule is tested by emptying the capsule contents into neutralizing broth and plating on blood agar. Manual capsule filling equipment with 5000 capsules/h output must be operated in a controlled environment at 20–25 °C and RH <30%. Broken capsule shells are not reworked because the API is hygroscopic and loses viability when exposed to ambient humidity above 60% RH. Package format is an aluminum foil blister with desiccant packets. Label claims for capsulated live vaccine are contingent on local veterinary registration. Published data for B26-T1200 in hard gelatin capsules is limited, so pilot stability is mandatory before commercial use. The capsule form is not appropriate for mass administration in large commercial flocks because individual bird handling is impractical above 500 birds/day per trained vaccination crew. Open capsule contents must not be mixed with drinking water because enteric coating fragments can block nipple drinkers and produce variable vaccine delivery.

Effervescent Tablet Water-Delivery Units in Remote Water Sources

Effervescent tablets are used where point-of-use reconstitution of clean water is not possible and vaccine handling must be simplified. The tablet matrix contains lyophilized live API at 25% w/w, citric acid at 30% w/w, sodium bicarbonate at 35% w/w, mannitol at 8% w/w and PEG 6000 at 2% w/w. Direct compression is performed at 8–12 kN on a rotary tablet press under RH <25%. Tablet hardness is maintained at 4–8 kp. Disintegration time in 200 mL water at 20 °C is less than 3 min. The resulting suspension must be consumed by the flock within 2 h. Water temperature above 30 °C reduces viable count by more than 1.0 log10 CFU within 30 min. Published data for B26-T1200 at higher temperatures are limited. The effervescent system is not suitable for water containing high calcium hardness because calcium carbonate precipitation may adsorb bacterial cells. Packaging is an aluminum foil blister with desiccant. Stored at 2–8 °C, the tablets retain viability for 12 months when protected from moisture. Uniformity of dosage units is tested according to USP <905>. The tablet is intended solely for oral drinking-water delivery and must not be injected or mixed with acidifiers. Airborne powder from broken tablets is a biohazard in the tableting suite; primary containment barriers and high-efficiency particulate air filtration are required during compression. The finished tablet does not require sterile preparation, but the water used for reconstitution must be potable and free of residual disinfectant. A single tablet is generally sized to treat 100–500 birds depending on the dose volume and drinking water consumption rate. The tablet format is not recommended for automatic proportioner use because the effervescent carrier does not form a stable stock solution; it is intended for tank or bucket mixing only.

Concentrated oral stock solutions for drinking-water proportioner pumps impose a narrow viability envelope because the live cells remain suspended in aqueous medium for prolonged periods before dilution. A stock solution prepared from lyophilized B26-T1200 in stabilized water containing 0.1% w/v skim milk or 0.05% w/v purified polysorbate 80 is injected into the water line at a 1:100 proportional dilution. The stock is held at 2–8 °C with continuous magnetic stirring at 50 rpm. Viable count decline after 8 h is typically less than 0.5 log10 CFU/mL when the stock is kept cold and protected from light. Shear from peristaltic pump heads and long tubing can damage bacterial cell membranes; tubing length should not exceed 10 m and internal diameter should be at least 3 mm to reduce shear rate. The final drinking water must be free of chlorine residues and orthophosphate scale inhibitors. Proportioner calibration is verified daily with a conductivity tracer; deviation from the 1:100 target must not exceed ±10%. The solution presentation is not suitable for storage beyond the vaccination day. No published pharmacopoeial monograph specifies a shelf life for B26-T1200 liquid stock solutions; a product-specific in-use stability protocol is required before first commercial use. The stock solution must not be returned to the refrigerator after line installation because retrograde contamination from the drinking water circuit can introduce Enterobacteriaceae and Pseudomonas species. All wetted parts of proportioner pumps must be cleaned with cold neutral detergent after each vaccination day; hypochlorite or hot water above 40 °C is contraindicated for first-line cleaning because residual organic matter can form biofilms that protect bacterial pathogens. The solution form is therefore reserved for farms with calibrated proportioners and trained vaccination crews, not for open-system bucket delivery where later-time viability cannot be documented.